The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
Open accessAbstract
Significance: Inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 predispose to very high risks of breast and ovarian cancer. For carriers of these mutations, risk-reducing surgery significantly reduces morbidity and mortality. General population screening for BRCA1 and BRCA2 mutations in young adult women could be feasible if accurate estimates of cancer risk for mutation carriers could be obtained. We determined that risks of breast and ovarian cancer for BRCA1 and BRCA2 mutation carriers ascertained from the general population are as high as for mutation carriers ascertained through personal or family history of cancer. General screening of BRCA1 and BRCA2 would identify many carriers who are currently not evaluated and could serve as a model for population screening for genetic predisposition to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Principles and Practice of Screening for Disease.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-5-1085_2 · Cited by 3,066
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., McGuire, A. L., Nussbaum, R. L., O’Daniel, J. M., Ormond, K. E., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.73 · Cited by 2,541
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Self-citationMeta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · cited 2×
“Imputation was carried out independently based on risks estimated from two previous studies (3, 20) as well as from this one.”
MethodResultDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996) · Nature Genetics · doi:10.1038/ng1096-185 · Cited by 770
Khoury, M. J., Gwinn, M., Yoon, P. W., Dowling, N., Moore, C. A., & Bradley, L. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815699d0 · Cited by 705
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Self-citationPopulation Screening in the Age of Genomic Medicine
Khoury, M. J., McCabe, L. L., & McCabe, E. R. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra013182 · Cited by 456
Gayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A. J., Stratton, M. R., & Easton, D. (1997) · Nature Genetics · doi:10.1038/ng0197-103 · Cited by 442
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2747 · Cited by 409
On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
Begg, C. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1221 · Cited by 201
Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer
Weitzel, J. N., Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, J. O., Blazer, K. R., Palomares, M. R., Lowstuter, K. J., & MacDonald, D. J. (2007) · JAMA · doi:10.1001/jama.297.23.2587 · Cited by 199
Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women
Metcalfe, K. A., Poll, A., Royer, R., Llacuachaqui, M., Tulman, A., Sun, P., & Narod, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0712 · Cited by 190
Awareness and Utilization of BRCA1/2 Testing Among U.S. Primary Care Physicians
Bellcross, C. A., Kolor, K., Goddard, K. A. B., Coates, R. J., Reyes, M., & Khoury, M. J. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.09.027 · Cited by 166
A Population Approach to Precision Medicine
Khoury, M. J., Gwinn, M. L., Glasgow, R. E., & Kramer, B. S. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.02.012 · Cited by 163
Rehder, C. W., David, K. L., Hirsch, B., Toriello, H. V., Wilson, C. M., & Kearney, H. M. (2013) · Genetics in Medicine · doi:10.1038/gim.2012.169 · Cited by 158
Antoniou, A. C., Pharoah, P. D. P., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Olsson, H. L., Johannsson, O. T., Borg, Å., Pasini, B., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024133 · Cited by 141
Tryggvadóttír, L., Sigvaldason, H., Ólafsdóttir, G. H., Jonasson, J. G., Jónsson, Þ., Tulinius, H., & Eyfjord, J. E. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj012 · Cited by 131
Møller, P., Hagen, A. I., Apold, J., Mæhle, L., Clark, N., Fiane, B., Løvslett, K., Hovig, E. J., & Vabø, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.023 · Cited by 121
Gene Patenting — The Supreme Court Finally Speaks
Kesselheim, A. S., Cook-Deegan, R. M., Winickoff, D. E., & Mello, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmhle1308199 · Cited by 103
Chong, H. K., Wang, T., Lu, H., Seidler, S., Lu, H. Y., Keiles, S. B., Chao, E., Stuenkel, A. J., Li, X., & Elliott, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097408 · Cited by 86
Hirsh‐Yechezkel, G., Chetrit, A., Lubin, F., Friedman, E., Peretz, T., Gershoni, R., Rizel, S., Struewing, J. P., & Modan, B. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00152-5 · Cited by 65
Self-citationMetcalfe, K. A., Poll, A., Llacuachaqui, M., Nanda, S., Tulman, A., Mian, N. C., Sun, P., & Narod, S. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01499.x · Cited by 58
Pujol, P., Stoppa‐Lyonnet, D., Frébourg, T., Blin, J., Picot, M., Lasset, C., Dugast, C., Berthet, P., Paillerets, B. B., Sobol, H., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2669-9 · Cited by 43
Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers
Finkelman, B. S., Rubinstein, W. S., Friedman, S. J., Friebel, T. M., Dubitsky, S., Schonberger, N. S., Shoretz, R., Singer, C. F., Blum, J. L., Tung, N., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8133 · Cited by 43
Ashkenazi Jewish Screening in the Twenty-first Century
Klugman, S. D., & Gross, S. J. (2010) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2010.01.001 · Cited by 28
Cited by
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
Developing and evaluating polygenic risk prediction models for stratified disease prevention
Chatterjee, N., Shi, J., & García-Closas, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.27 · Cited by 697
Multiple primary tumours: challenges and approaches, a review
Vogt, A., Schmid, S., Heinimann, K., Frick, H., Herrmann, C., Cerny, T., & Omlin, A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000172 · Cited by 628
Metadata
- Authors
- Gabai-Kapara, E., Lahad, A., Kaufman, B., Friedman, E., Segev, S., Renbaum, P., Beeri, R., Gal, M., Grinshpun-Cohen, J., Djemal, K., Mandell, J. B., Lee, M. K., Beller, U., Catane, R., King, M.-C., & Levy-Lahad, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-09-05
- Volume
- 111
- Issue
- 39
- Pages
- 14205-14210
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2080103464
- Cited by
- 342
- References
- 33
- FWCI
- 19.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.